Skip to Content
Merck
All Photos(1)

Documents

Y0000527

Rocuronium for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Rocuronium bromide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C32H53BrN2O4
CAS Number:
119302-91-9
Molecular Weight:
609.68
MDL number:
MFCD00867768
UNSPSC Code:
41116107
PubChem Substance ID:
329831004
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

rocuronium

manufacturer/tradename

EDQM

solubility

H2O: 100 mg/mL, clear, light yellow

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

[Br-].CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CCCC6)CC=C

InChI

1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1

InChI key

OYTJKRAYGYRUJK-FMCCZJBLSA-M

Gene Information

human ... CHRNA1(1134) , CHRNB1(1140) , CHRND(1144) , CHRNE(1145) , CHRNG(1146)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Rocuronium for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Aminosteroid; neuromuscular blocker for anaesthesia

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301,H335

Hazard Classifications

Acute Tox. 3 Oral - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Adrienn Pongrácz et al.
Anesthesiology, 119(1), 36-42 (2013-05-15)
Doses of sugammadex required to reverse deep, moderate, and shallow rocuronium-induced neuromuscular blockade have been established. However, no adequate doses for the reversal of reappearance of four twitches of train-of-four (TOF) stimulation (threshold TOF-count-four) have been established. This single-center, randomized
Low-dose sugammadex reversal: there is no such thing as a free lunch.
Aaron F Kopman et al.
Anesthesiology, 119(1), 10-12 (2013-05-15)
Yuji Kadoi et al.
The journal of ECT, 29(1), 33-36 (2012-10-12)
This study was conducted to (1) compare the recovery times from rocuronium-induced muscle relaxation after reversal with sugammadex between young and elderly patients undergoing electroconvulsive therapy (ECT), and (2) to examine the existence of a correlation between cardiac index and
Yian Xing et al.
The Journal of surgical research, 185(1), 198-205 (2013-07-03)
Muscles innervated by the facial nerve show different sensitivities to muscle relaxants than muscles innervated by somatic nerves, especially in the presence of facial nerve injury. We compared the evoked electromyography (EEMG) response of orbicularis oris and gastrocnemius in with
P H M Sadleir et al.
Anaesthesia and intensive care, 42(1), 93-96 (2014-01-30)
Sugammadex is a selective binding agent for aminosteroid neuromuscular blockers whose use is increasing in anaesthetic practice. We present three cases of severe anaphylaxis coincident with sugammadex administration. Subsequent intradermal testing confirmed sugammadex as the triggering agent, with all patients
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service